Product image of Lenalidomide supplied by GNH India

Lenalidomide

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide

Lenalidomide, the active ingredient in Lenalidomide, is an immunomodulatory agent presented as a tablet for oral use. It is classified as an antineoplastic drug and treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH India supplies Lenalidomide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lenalidomide is employed in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow clones.
  • Multiple Myeloma: improves progression‑free survival and overall response rates in combination regimens.
  • Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.
  • Mantle Cell Lymphoma: contributes to disease control when used with other agents.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4CRBN E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. This leads to anti‑angiogenic effects, modulation of cytokine production, enhanced immune cell activation, and direct inhibition of malignant cell proliferation.

Side Effects

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: lowered platelet levels, potentially causing bleeding.
  • Fatigue: persistent tiredness affecting daily activities.
  • Diarrhea: loose stools that may lead to dehydration.
  • Rash: skin irritation or erythema.
  • Nausea: upset stomach, sometimes with vomiting.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Secondary primary malignancies: emergence of new cancers.
  • Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hepatotoxicity: significant liver enzyme elevation.
  • Embryo‑fetal toxicity: high risk of birth defects if exposure occurs during pregnancy.

Precautions & Warnings

  • Before initiating Lenalidomide therapy, consider patient-specific factors and monitor appropriately.
  • Pregnancy risk: contraindicated in pregnancy due to teratogenicity; ensure effective contraception.
  • Blood counts: monitor complete blood count regularly to detect cytopenias.
  • Thrombotic risk: assess need for prophylactic anticoagulation in high‑risk patients.
  • Renal function: adjust monitoring in patients with impaired kidney function.
  • Drug interactions: review concomitant medications for potential interactions.
  • Store at ambient temperature: keep tablets below 25°C in the original container, protected from moisture and light.

Avoid Interactions

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce Lenalidomide exposure.
  • Anticoagulants (e.g., warfarin): increased risk of bleeding.
  • Immunosuppressants: heightened infection risk.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors: may modestly increase Lenalidomide levels.
  • NSAIDs: can exacerbate thrombocytopenia.
  • Live vaccines: reduced efficacy and potential safety concerns.

Frequently Asked Questions

Lenalidomide is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with deletion of chromosome 5q, and mantle cell lymphoma, typically as part of combination therapy in adult patients.

Lenalidomide binds to cereblon, a component of the CRL4CRBN E3 ubiquitin ligase complex, altering its activity to degrade transcription factors Ikaros and Aiolos. This results in anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects that inhibit malignant cell growth.

The specific dose of Lenalidomide is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Patients should follow the dosage instructions provided by their healthcare professional.

Lenalidomide is classified as pregnancy category X because it can cause severe birth defects and fetal harm. It is contraindicated in pregnancy, and effective contraception is required for both male and female patients of reproductive potential. Use during breastfeeding is not recommended.

To request Lenalidomide, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, offering a distinct mechanism of action compared with proteasome inhibitors or monoclonal antibodies. It is often combined with dexamethasone or other agents to enhance efficacy, and its oral formulation provides convenience over injectable alternatives.

Lenalidomide tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not store in humid environments such as bathrooms.

Lenalidomide is taken orally, usually once daily in tablet form, with or without food as directed by the prescribing clinician. The exact schedule, including any treatment cycles and rest periods, is individualized based on the therapeutic regimen.

Serious risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, as well as venous thromboembolism, secondary primary malignancies, and embryo‑fetal toxicity. Patients should be monitored closely for these events throughout treatment.

Lenalidomide should not be used by individuals who are pregnant, planning to become pregnant, or not using effective contraception. It is also contraindicated in patients with known hypersensitivity to the drug or its excipients, and caution is advised in those with severe renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT